Post-partum Hemorrhage (PPH)
8
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)
Intra-Umbilical Vein Oxytocin Injection as an Adjunct to Active Management of the Third Stage of Labour
Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesarean Section in Antenatal Low-risk Patients
Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery
Safety and Effectiveness of the Alma System in Treating Primary Postpartum Hemorrhage
Risk Factors for Postpartum Hemorrhage in Patients With Histologically Verified Placenta Accreta
Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT)
Misoprostol for Treatment of Postpartum Haemorrhage (PPH) in Home Births